Therapeutic Effects of Vitamin E in Non-alcoholic Fatty Liver Disease: An Open-Labeled Clinical Trial
DOI:
https://doi.org/10.31351/vol31iss2pp135-143Keywords:
nonalcoholic fatty liver disease (NAFLD), steatosis score, vitamin EAbstract
Abstract: non-alcoholic fatty liver disease (NAFLD) is one of the widespread chronic liver diseases; it is ranging from simple fat buildup in the liver (steatosis) to non-alcoholic steatohepatitis (NASH) presence of inflammation and hepatocyte injury. This study aims to assess the effect of vitamin E on the degree of fatty infiltration in the liver, liver enzymes, and lipid profile.
A prospective open-labeled clinical trial involved (39) Participants diagnosed with NAFLD depending on ultrasonography findings, they were administered vitamin E 800IU\day for 12wks and advised to take low fat, low carbohydrate diet and to do regular sport. Steatosis score, liver enzymes, fasting blood sugar and lipid profile were measured at baseline and repeated at 4wks and 12wks of the study period. Results of this study found that vitamin E reduces steatosis score significantly at 12wks (p=0.0001), while liver enzymes ALT and ALP did not show significant difference throughout the study period at 12wks (p=0.081 for ALT, P=0.117 for ALP) only AST showed significant difference ( p=0.008 at 12wks ), total cholesterol and triglyceride were reduced significantly (p=0.0001 for both) at 4wks and 12wks where HDL and fasting blood glucose were not altered significantly through the study period. In conclusion, vitamin E and lifestyle modifications have a positive impact on patients with NAFLD by reducing steatosis score, lipid profile, and BMI
How to Cite
Publication Dates
References
Alam S, Jahid Hasan M, Khan MAS, Alam M, Hasan N. Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient. J Transl Intern Med. 2019;7(3):106–14.
Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, et al. Non-Alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; New Kids on the Block. Curr Vasc Pharmacol. 2019;18(2):172–81.
Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for Liver Transplantation. Transplantation. 2019;103(1):22–7.
Kothari S, Dhami-Shah H, Shah SR. Antidiabetic drugs and statins in nonalcoholic fatty liver disease. J Clin Exp Hepatol [Internet]. 2019;9(6):723–30. Available from: https://doi.org/10.1016/j.jceh.2019.06.003
Jalali M, Rahimlou M, Mahmoodi M, Moosavian SP, Symonds ME, Jalali R, et al. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled . Pharmacol Res [Internet]. 2020;159(March):104799. Available from: https://doi.org/10.1016/j.phrs.2020.104799
Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65(8):1017–25.
Nafeer SA, Zalzala MH. Possible amelioration of the severity of nutritional steatohepatitis by guggulsterone in mice. Iraqi J Pharm Sci. 2019;28(1):17–23.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
